Each film coated tablet contains Dasatinib 100 mg as Dasatinib Monohydrate INN.
Dasatinib is indicated for the treatment of adult patients with · Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. · Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib. · Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is indicated for the treatment of pediatric patients 1 year of age and older with · Ph+ CML in chronic phase. · Newly diagnosed Ph+ ALL in combination with chemotherapy.
Each film coated tablet contains Dasatinib 100 mg as Dasatinib Monohydrate INN.
Dasatinib is indicated for the treatment of adult patients with · Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. · Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib. · Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is indicated for the treatment of pediatric patients 1 year of age and older with · Ph+ CML in chronic phase. · Newly diagnosed Ph+ ALL in combination with chemotherapy.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.